In March 2019, the Secretary of State for Health and Social Care commissioned NHS England and NHS Improvement to review NHS systems and processes to identify and recommend any action necessary to address any barriers to clinically appropriate prescribing of cannabis-based products for medicinal use (CBPMs) on the NHS.
The findings and recommendations are available in the document ‘Barriers to accessing cannabis-based products for medicinal use on NHS prescription‘.
Following the Government’s announcement on the 1 November 2018 that it would reschedule reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the rescheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in the NHS and in private practice in England.
A further letter has been issued which provides additional guidance to clinicians and organisations following the rescheduling of cannabis-based products for medicinal use. This clarifies the status of the clinical guidance issued, and provides further clarification in relation to synthetic cannabinoids for medicinal use.
Following the publication of NICE guidance on Cannabis-Based Medicinal Products in November and December 2019, a further letter has been issued to share details of the guidance. It also includes other new resources and reminds those who are in the position of deciding whether to prescribe CBPMs of the current process for prescribing.
- Guidance to clinicians: The process for prescribing Cannabis-based products for medicinal use
- Prescribing of THC:CBD spray (Sativex®) in line with NICE NG144
A set of clinical frequently asked questions (FAQs) is available to provide further support to prescribers.